Molecular Profile Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 30 of 30 entries

Molecular Profile	Indication/Tumor Type	Response Type	Relevant Treatment Approaches	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
BRAF G466V	Advanced Solid Tumor	no benefit		Vemurafenib	Clinical Study - Cohort	Actionable	In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in an objective response in only 4% (1/23) of patient with advanced solid tumors harboring non-V600 BRAF mutations, 1 of the non-responding patients harbored BRAF G466V (PMID: 29320312; NCT02091141).	29320312
BRAF G466V	colorectal cancer	not predictive		Irinotecan + Panitumumab	Case Reports/Case Series	Actionable	In a clinical case study, a patient with metastatic colorectal cancer harboring BRAF G466V, and with wild-type RAS and NF1, demonstrated tumor regression following treatment with Vectibix (panitumumab) plus Camptosar (irinotecan) (PMID: 28783719).	28783719
BRAF G466V	lung non-small cell carcinoma	no benefit		Vemurafenib	Case Reports/Case Series	Actionable	In a Phase II trial, Zelboraf (vemurafenib) treatment did not result in response in the cohort of 15 non-small cell lung cancer patients with non-V600 BRAF mutations, which included 3 patients harboring BRAF G466V, and enrollment in this cohort was discontinued (PMID: 31959346; NCT02304809).	31959346
BRAF G466V	Advanced Solid Tumor	no benefit	MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor	Trametinib	Case Reports/Case Series	Actionable	In a Phase II trial (NCI-MATCH), Mekinist (trametinib) treatment did not demonstrate clinical activity in patients with advanced solid tumors or lymphoma harboring BRAF fusion or non-V600 mutations, resulted in progressive disease in a patient with tumor of unknown primary harboring BRAF G466V (PMID: 31924734; NCT02465060).	31924734
BRAF G466V	lung adenocarcinoma	no benefit	MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor	Trametinib	Case Reports/Case Series	Actionable	In a Phase II trial (NCI-MATCH), Mekinist (trametinib) treatment did not demonstrate clinical activity in patients with advanced solid tumors or lymphoma harboring BRAF fusion or non-V600 mutations, resulted in progressive disease in a patient with lung adenocarcinoma harboring BRAF G466V (PMID: 31924734; NCT02465060).	31924734
BRAF G466V	colorectal cancer	not predictive		Irinotecan + Panitumumab	Case Reports/Case Series	Actionable	In a clinical study, the combination of Vectibix (panitumumab) with Camptosar (irinotecan) as a third-line therapy resulted in a partial response with 6.1 months progression-free survival in a patient with metastatic colorectal cancer harboring BRAF G466V (PMID: 31515458).	31515458
BRAF G466V	lung adenocarcinoma	predicted - sensitive	MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor	Dabrafenib + Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, first-line treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) resulted in a partial response after 3 months in a patient with metastatic lung adenocarcinoma harboring BRAF G466V (PMID: 38283732).	38283732
BRAF G466V	colorectal cancer	sensitive		Cetuximab	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Erbitux (cetuximab) reduced ERK signaling and resulted in tumor regression in a colorectal cancer patient-derived xenograft (PDX) model harboring BRAF G466V, and wild-type RAS and NF1 (PMID: 28783719).	28783719
BRAF G466V	colorectal cancer	sensitive	MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor	Trametinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Mekinist (trametinib) delayed tumor growth in a colorectal cancer patient-derived xenograft (PDX) model harboring BRAF G466V, and wild-type RAS and NF1 (PMID: 28783719).	28783719
BRAF G466V	colorectal cancer	predicted - resistant		Vemurafenib	Preclinical - Pdx	Actionable	In a preclinical study, Zelboraf (vemurafenib) did not inhibit ERK signaling or tumor growth in a colorectal cancer patient-derived xenograft (PDX) model harboring BRAF G466V, and wild-type RAS and NF1 (PMID: 28783719).	28783719
BRAF G466V	colorectal cancer	sensitive		Cetuximab	Preclinical - Pdx	Actionable	In a preclinical study, Erbitux (cetuximab) treatment inhibited Erk signaling and reduced tumor growth in a patient-derived xenograft (PDX) model of colorectal cancer harboring BRAF G466V (PMID: 30559419).	30559419
BRAF G466V	colorectal cancer	resistant		PLX8394	Preclinical - Pdx	Actionable	In a preclinical study, PLX8394 treatment did not inhibit Erk signaling or reduce tumor growth in a patient-derived xenograft (PDX) model of colorectal cancer harboring BRAF G466V (PMID: 30559419).	30559419
BRAF G466V	colorectal cancer	predicted - resistant		Vemurafenib	Preclinical - Pdx	Actionable	In a preclinical study, Zelboraf (vemurafenib) treatment did not inhibit Erk signaling or reduce tumor growth in a patient-derived xenograft (PDX) model of colorectal cancer harboring BRAF G466V (PMID: 30559419).	30559419
BRAF G466V	colorectal cancer	sensitive		Cetuximab + PLX8394	Preclinical - Pdx	Actionable	In a preclinical study, PLX8394 treatment in combination with Erbitux (cetuximab) inhibited tumor growth in a patient-derived xenograft (PDX) model of colorectal cancer harboring BRAF G466V, but did not improve efficacy compared to Erbitux (cetuximab) treatment alone (PMID: 30559419).	30559419
BRAF G466V	colorectal cancer	sensitive		Cetuximab + Vemurafenib	Preclinical - Pdx	Actionable	In a preclinical study, Zelboraf (vemurafenib) treatment in combination with Erbitux (cetuximab) inhibited tumor growth in a patient-derived xenograft (PDX) model of colorectal cancer harboring BRAF G466V, but did not improve efficacy compared to Erbitux (cetuximab) treatment alone (PMID: 30559419).	30559419
BRAF G466V	lung non-small cell carcinoma	predicted - sensitive		Osimertinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Tagrisso (osimertinib) inhibited growth of a patient-derived non-small cell lung cancer line harboring BRAF G466V in culture (PMID: 39637338).	39637338
BRAF G466V	lung non-small cell carcinoma	sensitive		Dasatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) induced apoptosis in non-small cell lung cancer cells expressing BRAF G466V in culture (PMID: 22649091).	22649091
BRAF G466V	lung non-small cell carcinoma	sensitive		TAK-632	Preclinical - Cell culture	Actionable	In a preclinical study, TAK-632 inhibited proliferation of non-small cell lung cancer cells harboring BRAF G466V in culture (PMID: 27523909).	27523909
BRAF G466V	lung non-small cell carcinoma	no benefit		Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring BRAF G466V demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).	27523909
BRAF G466V	lung non-small cell carcinoma	sensitive	MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) reduced ERK signaling and inhibited proliferation of non-small cell lung cancer cell lines harboring BRAF G466V in culture (PMID: 28783719).	28783719
BRAF G466V	lung non-small cell carcinoma	sensitive	MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) resulted in decreased proliferation and increased apoptosis, and enhanced ERK inhibition compared to either agent alone in a non-small cell lung cancer cell line harboring BRAF G466V in culture (PMID: 28947956).	28947956
BRAF G466V	lung adenocarcinoma	sensitive		PLX8394	Preclinical - Cell culture	Actionable	In a preclinical study, PLX8394 decreased growth of lung adenocarcinoma cell lines harboring BRAF G466V in culture (PMID: 27834212).	27834212
BRAF G466V	lung cancer	predicted - sensitive		RMC-4550	Preclinical - Cell culture	Actionable	In a preclinical study, RMC-4550 inhibited Erk phosphorylation and proliferation of lung cancer cells harboring BRAF G466V in culture (PMID: 30104724).	30104724
BRAF G466V	lung cancer	predicted - sensitive		PLX8394	Preclinical - Cell culture	Actionable	In a preclinical study, lung cancer cells harboring BRAF G466V demonstrated sensitivity to PLX8394 treatment in culture (PMID: 30559419).	30559419
BRAF G466V	lung cancer	predicted - sensitive		CFT1946	Preclinical - Cell culture	Actionable	In a preclinical study, CFT1946 treatment inhibited proliferation of a lung cancer cell line harboring heterozygous BRAF G466V in culture (Cancer Res 2022;82(12_Suppl):Abstract nr 2158).	detail...
BRAF G466V	lung non-small cell carcinoma	sensitive		IHMT-RAF-128	Preclinical - Cell culture	Actionable	In a preclinical study, IHMT-RAF-128 inhibited proliferation in a non-small cell lung cancer cell line harboring BRAF G466V in culture (PMID: 37164118).	37164118
BRAF G466V	lung non-small cell carcinoma	sensitive		SIJ777	Preclinical - Cell culture	Actionable	In a preclinical study, SIJ777 inhibited proliferation of a non-small cell lung cancer cell line harboring BRAF G466V in culture (PMID: 33917428).	33917428
BRAF G466V	lung non-small cell carcinoma	predicted - sensitive		Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tarceva (erlotinib) inhibited growth of a non-small cell lung cancer cell line harboring BRAF G466V in 2D and 3D culture (PMID: 39637338).	39637338
BRAF G466V	lung non-small cell carcinoma	predicted - sensitive		PF-07799933	Preclinical - Biochemical	Actionable	In a preclinical study, PF-07799933 inhibited Erk phosphorylation in non-small cell lung cancer cells harboring BRAF G466V in culture (PMID: 38691346).	38691346
BRAF G466V	lung non-small cell carcinoma	sensitive		TAE226	Preclinical	Actionable	In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring BRAF G466V mutation in culture (PMID: 26090892).	26090892

Showing 1 to 30 of 30 entries

Filter rows:

Profile Name	BRAF G466V
Gene Variant Detail	BRAF G466V (loss of function)
Relevant Treatment Approaches	MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor

Molecular Profile Detail

Contact

Filtering

Sorting